INTRODUCTION
Circulating endothelial cells (CECs) and their progenitors, endothelial progenitor cells (EPCs), are being studied with increasing interest in oncology, particularly in relation to tumor angiogenesis. Recent studies have demonstrated elevated CEC count in patients with malignant diseases compared with healthy controls (1) (2) (3) (4) (5) (6) (7) . Several pioneering studies have demonstrated that CEC elevations are associated with tumor stage, tumor characteristics and prognosis (4, (8) (9) (10) . It has been experimentally demonstrated that chemotherapy causes a rapid induction of EPCs into the systemic circulation of mice, irrespective of the presence of tumor (11) . EPC mobilization may support tumor cell survival even during anticancer chemotherapy.
CECs and EPCs are currently determined by several different assay systems including the flow cytometry and immunomagnetic detection system using endothelial cell markers including CD31, CD34, and CD146, and progenitor cell markers including CD133 (12) . However, the markers and criteria that are used differ among studies (13, 14) .
The flow cytometry analysis has some limitations including standardization between different laboratories and difficulties in fresh blood shipping. Recently, a semi-automated system for the detection of CECs was developed. The CellSearch system (Veridex LLC, Raritan, NJ) is mostly automated but enables researchers to detect endothelial cells visually using the immunofluorescence system. This system allows standardized analyses in different laboratories and shipment of blood samples in special tubes containing preservatives.
In this study, we used the CellSearch system to examine baseline CEC count and CEC alterations during systemic chemotherapy in association with clinicopathological 5 parameters and treatment responses to preoperative chemotherapies. CECs were stained with an additional antibody against CD34 and its expression was evaluated using an extra channel in the system.
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PATIENTS AND METHODS
Patients
Pathological analyses
Tumor biopsy specimens before preoperative chemotherapy were examined pathologically for tumor grade according to the Scarff-Bloom-Richardson grading system.
Tumor specimens were also examined for estrogen receptor (ER), progesterone receptor The MIB1/Ki67 labeling index was calculated by counting positively stained tumor cells per 1000 tumor cells in the hot spots. Tumors having an MIB1/Ki67 index >20% were categorized as rapidly proliferative (positive), and those having an index <20% were defined as slowly proliferative (negative).
Statistical analyses
Correlation analyses were performed to assess the associations between baseline CEC counts and tumor size, nodal status, grade, stage, ER, PgR and HER2 statuses, tumor phenotype, and tumor response. Correlation analysis was performed using the MannWhitney test for two independent samples and the Kruskal-Wallis test for more than two independent samples. Logistic regression analysis was used to identify parameters associated with pathological response. Changes in CEC and CEP numbers were analyzed using repeated measures ANOVA. Statistical analyses were performed using JMP (ver.
8.0.1; SAS Institute Japan, Tokyo, Japan). P values of <0.05 were considered statistically significant.
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RESULTS
Characteristics of CECs detected by the CellSearch system
The expression of CD34, which is a commonly used marker for endothelial cells, was examined in CECs detected by the CellSearch system. As shown in Figure 1 , 88% (4539 of 5183 cells) of CECs from patients with operable breast cancer before treatment were CD34 positive. Table 1 shows the characteristics of the patients and their baseline CEC and CD34 + CEC counts in relation to clinicopathological parameters. CD34 expression was not measured in two patients with operable breast cancer. CEC count was higher in metastatic or recurrent breast cancer patients than in patients with operable breast cancer (P = 0.0275).
Patient characteristics and correlations with clinicopathological parameters
Among patients with operable breast cancer, those with triple-negative cancers had significantly higher CEC and CD34 + CEC counts than those with other types of cancer (P = 0.0387 and 0.0377, respectively). Similarly, patients with PR-negative cancers showed higher CEC and CD34 + CEC counts than those with PR-positive cancers (P = 0.0413 and 0.0437, respectively). In patients with metastatic or recurrent breast cancer, patients with lung, liver or bone metastasis showed higher CEC counts than those with lymph node or skin metastasis (P = 0.037).
CEC and CD34 + CEC counts and responses to chemotherapy
In 35 patients with operable breast cancer, CEC and CD34 + CEC counts were examined according to pathological and clinical responses to preoperative chemotherapy.
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The pCR group showed lower numbers of baseline CD34 + CEC counts than the non-pCR group (P = 0.0416) (Figure 2 ). In addition, the pCR group showed a lower CD34-positive rate (CD34 + CEC count/total CEC count) than the non-pCR group (P = 0.0356) (Figure 2 ).
In the logistic regression analysis, CEC, CD34 + CEC, and CD34-positive rates were significantly associated with pCR in univariate analyses (P = 0.046, 0.027, and 0.01, respectively) ( Table 2 ). In multivariate analyses, the CD34-positive rate remained significant for pCR (P = 0.021) ( Table 2 ). CEC counts, CD34 + CEC counts, and CD34-positive rate did not show any association with clinical responses (data not shown). 
Changes in CEC and
DISCUSSION
At present, no standardized method is available to determine CEC and EPC counts, which makes reported data on CEC variable. The CellSearch system is a commercially available semi-automated system that enables standardized determination of CECs. A recent study reported that increases in CECs detected by the CellSearch system during antiangiogenic treatment were associated with improved outcome in metastatic breast cancer patients treated with bevacizumab and standard chemotherapy (15) . However, CEC count by the CellSearch system is yet to be examined in patients with operable breast cancer. Thus, we examined clinical utility of CEC count by this system in patients with operable breast cancer, in particular during preoperative systemic chemotherapy.
Our results showed that patients with triple-negative tumors had higher CEC and CD34 + CEC counts compared with those who had other types of breast cancer. Intratumoral expression levels of vascular endothelial growth factor (VEGF)-A, stromal-derived growth factor (SDF)-1α and granulocyte colony-stimulating factor (G-CSF), all of which are known to mobilize EPCs (16, 17) , are reported to be higher in basal-like tumors, which are a major subtype of triple-negative breast cancers (18) . A cDNA microarray study with a series of 138 tumors (80 luminal A, which is an ER-positive subtype, and 58 basal-like)
showed that basal-like tumors overexpressed genes associated with angiogenesis, such as VEGF genes compared with luminal-type tumors. In contrast, genes associated with antiangiogenesis, such as thrombospondin, type I, domain containing 1 (THSD1) and THSD4, were underexpressed in basal-like tumors (19) . Patients with ER-positive tumors have been noted to have higher serum levels of endostatin, an intrinsic negative regulator of angiogenesis, compared to those with ER-negative tumors (20) . Although the origin of
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CECs determined by the CellSearch system is unclear, our results are in agreement with these reports and suggest that triple-negative breast cancers have more angiogenic
properties than other types of breast cancer.
Several recent studies have reported that elevated CEC count in cancer patients return to normal levels in response to systemic treatment (6, 7, (20) (21) (22) (23) . In the present study, the pCR group showed lower CD34 + CEC count and a lower CD34-positive rate at baseline compared to the non-pCR group. In the logistic regression analysis, CD34 + CEC count and the CD34-positive rate showed higher predictive power for pCR compared to CEC count. 
